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ABSTRACT 
Background Informed consent is a mainstay of clinical practice, with both moral and legal 
force. Material disclosure about extreme treatments, however, is unlikely to convey the full 
impact of the experience of treatment. Informed consent may be flawed under such cir-
cumstances. 
Aims To compare expressed satisfaction with pre-treatment information to satisfaction af-
ter experiencing autologous stem cell transplantation (ASCT) for recurrent lymphoma. 
Methods A qualitative, narrative-based cohort study has been conducted in a Teaching 
hospital Bone Marrow Transplant unit at Westmead Hospital, Sydney, Australia. The cohort 
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consisted of ten transplant recipients and nine of their nominated lay carers. The Outcome 
measure was satisfaction expressed in narrative interviews at the time of transplantation 
and three months later. We used discourse analytic techniques to examine the narratives. 
Results Both patients and carers expressed high satisfaction with the information given by 
individual clinicians and by speakers at a formal Information Day held before transplanta-
tion. At the first interview, neither patients nor carers commented much on the forthcom-
ing ordeal of chemotherapy and bone marrow ablation, although all patients had under-
gone previous chemotherapy. At the second interview, the ordeal dominated the narra-
tives, and retrospective dissatisfaction with information was common.  
Conclusions This study suggests that information about treatment theories and protocols 
can be satisfactorily communicated, but personal experience of suffering defies communi-
cation. This finding has serious implications for the practices involved in obtaining informed 
consent and for the very notion of informed consent. 
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INTRODUCTION 
Informed consent is one pillar of modern clinical practice 1-17. It is meant to confirm a rela-
tionship of trust and understanding between patient and doctor. Complete information is 
supposedly provided in spoken and/or written form, so that the patient knows the nature 
of her treatment, its risks and benefits, and its possible outcomes. Informed consent is itself 
supported by moral and legal pillars. It is morally good because ideally it involves truth, re-
lationship, trust, free choice and exchange of knowledge – all construed as ‘goods’ in the 
context of medical practice and within the context of Western liberalism. It is legally good 
because the patient must have a general understanding of what will be done, otherwise the 
treating doctor is open to a charge of battery. 
There are, however, some who doubt the validity of informed consent on both moral and 
legal grounds. Some moralists believe that it represents an unattainable ideal, particularly 
in the context of serious illness and extreme treatment 6 18 19. The High Court in Australia 
does not consider informed consent to be a clear and distinct concept, nor helpful in cases 
involving alleged negligence 20. Despite these misgivings, however, conventional text-books 
of bioethics from different English-speaking countries emphasize its importance as a main-
stay of respect for autonomy and of sound medical practice 21 22. 
Its place is therefore well-established. This article examines its efficacy among patients un-
dergoing the taxing and debilitating treatment of autologous stem-cell transplantation 
(ASCT) for recurrent lymphoma in a bone-marrow transplant unit at Westmead Hospital, 
western Sydney, Australia. It is a purely qualitative study that concentrates, not on recall of 
detail of the information given, but on the satisfaction expressed by patients and their car-
ers before and after the transplant. 
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MATERIAL AND METHODS 
This study examines the appraisal by patients and their carers of the medical information 
provided individually by clinicians, and at the Information Day run by the Westmead Hospi-
tal for all bone-marrow recipients and their nominated carers. It does so by drawing on re-
sults from a prospective, ongoing, two-year study of a sequential sample of patients and 
their carers treated at the BMT Unit at Westmead Hospital, Sydney, Australia. All patients 
had recurrent lymphoma following chemotherapy, with or without radiotherapy. All were 
assessed as suitable for autologous stem cell harvest, and for stem cell transplantation after 
high dose chemotherapy (ASCT). All patients and their carers gave consent to interviews 
during hospital admission for transplantation, at three months after transplantation, and at 
six month intervals for two years. 
The study received ethical approval from the University of Sydney and from Westmead 
Hospital. Informed consent was obtained from all participants. All names have been sup-
pressed, and pseudonyms used. Table 1 shows demographic data about the patients and 
their matching carers. The sample represents well the ethnic diversity of Western Sydney. 
 
Table 1:  Demographic data of the patients and their matching carers* 
Patients Sex Decade Ethnicity Occupation Carers Sex Decade Ethnicity Occupation Relationship 
Abby F 3 White 
Australian 
Office man-
ager 
Bron-
nie 
F 6 White 
Australian 
Housewife Mother 
Colin M 7 Mixed-
race 
South 
African 
Small busi-
ness owner 
Delia F 6 Mixed-
race 
South 
African 
Marine un-
derwriter 
Wife 
Evelyn F 4 Chinese Health trans-
lator 
Francis M 4 Chinese Alternative 
medical 
practitioner 
Husband 
Grace F 7 White 
British 
Office worker Henry M 7 White 
Australian 
Retired Husband 
Ingrid F 7 White 
Australian 
Volunteer 
health sup-
port worker 
Justin M 4 White 
Australian 
Radiation 
oncology 
technician 
Son 
Kevin M 6 White 
Australian 
Business di-
rector and 
manager 
Louise F 6 White 
Australian 
Animal 
breeder 
Wife 
Norah F 4 Chinese IT recruitment Marvin M 4 Chinese IT manager Husband 
Pegah F 4 Lebanese Housewife Omar
#
 M ND Lebanese Small busi-
ness assis-
tant 
Husband 
Quentin M 4 White 
Australian 
Business 
manager 
Ruby F 4 White 
Australian 
Nurse Wife 
Tony M 7 Italian Businessman Sigrid F 6 White 
Australian 
Housewife Wife 
*Ages are given by decade only. 
#
 The carer code-named Omar declined interview. F, female; IT, information technology; M, male; ND, not determined. 
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The cohort consists of 10 patients (six female; four male) and nine carers (five female; four 
male). Carers were nominated by the patients. One carer declined to participate in the 
study because he deemed his English language ability to be too poor. Interviews were con-
ducted by two non-medical academic researchers (CFCJ and CM). Two sets of interviews 
have been analysed. The first set of interviews, conducted at the time of admission (Time 
1), consists of ten interviews with patients and eight interviews with carers. One carer was 
not available for interview at Time 1. The second set of interviews was conducted three 
months after discharge from hospital following the ‘transplant’ (Time 2) and consists of six 
interviews with patients and seven interviews with carers. Two patients had died since the 
first interview, one was too ill to be interviewed, and one had received his ‘transplant’ too 
recently to qualify for a second interview. One carer was excluded for the same reason, and 
one carer’s transcript of his second interview was not available at the time of review. Inter-
views at Time 1 were designed to elicit illness narratives. Interviews at Time 2 were semi-
structured. 
The discourse analytic methodology and its theoretical basis have been set out in some de-
tail elsewhere 23. The methodology is based on theories of the evolution and practices of 
discourse communities 24-26. Transcripts in this part of the study were read for two specific 
themes – 1) appraisal of the quality and content of medical information given by the clinical 
staff both individually and during the Information Day; and 2) perceptions of the impact of 
the ‘transplant’ episode and its aftermath as an ordeal 27 for the ‘transplant’ recipient. Each 
‘instance of mention’ of these two themes was coded and extracted into a separate file. We 
emphasise that we have examined the satisfaction that patients and carers express about 
the information proffered, rather than the accuracy of its recall and understanding. 
Material quoted in the results section has been minimally edited for sense and punctuation. 
Italics have been used for emphasis. 
RESULTS 
INTERVIEW AT TIME 1 
Medical information 
Six of 10 patients commented specifically on the excellence of the medical information, say-
ing that they felt well prepared for their transplantation experience. Colin (patient), for ex-
ample, described the Information Day as  
“…very informative. I was very impressed, actually”.  
No patient commented adversely on the quality or content of the Information Day. 
Five of the eight carers made eight specific comments, three carers praising without reser-
vation and two balancing their approval with minor reservations.  
Ordeal 
Both patients and carers all had previous first or second hand experience of the unpleasant 
side effects of chemotherapy. Despite this, only one of 10 patients specifically dwelt on 
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chemotherapy as an ordeal, and extrapolated that experience to the forthcoming trans-
plant. Colin (patient) said 
 Devastating. Yeah. It all depends what degree of chemo I was given, you know…sometimes the 
chemo is very strong, and it really puts me down.  
Four of eight carers, however, recorded the severity of chemotherapy’s impact on their 
charges. Delia (carer) made a typical comment: 
 And I don’t know much about what sort of chemo but it has knocked him. 
INTERVIEW AT TIME 2 
Medical information 
In the interviews at Time 2, all six patients commented on the quality and content of the 
medical information, but the appraisal was now overwhelmingly negative. The six patients 
made between them 25 comments, of which 20 were critical.  
Colin (patient), who found the Information Day so helpful at the first interview, said at the 
second: 
No I was not prepared, I mean I was not prepared…I never thought how bad it could be or how dan-
gerous it could be, how life threatening it could be…I could never ever comprehend what I was go-
ing through at the time.   
Six of seven carers spoke about the quality and content of the medical information, ad-
dressing the issue on 14 occasions. Four appraisals were supportive and 10 critical. A typical 
comment was offered by Henry, who cared for Grace. When asked whether he had been 
prepared for Grace’s suffering and death, he answered: 
No, didn’t have a clue.  I must say that it was mentioned that there were risks involved, but I just 
didn’t think this would happen to us. 
Ordeal 
All six patients made multiple mentions of ordeal, on 20 occasions. Colin (patient), for ex-
ample, says of the transplantation experience that it was: 
Very traumatic, and very frustrating, and it was not a pleasant thought at all, or feeling… I just 
wasn’t functioning.  
There was agreement that no one would want to go through the same experience once its 
severity has been understood. Abby (patient), who has experienced chemotherapy before, 
said 
Y’know, I just cannot go through this again. Y’know, it was way too much. It was just more than I 
ever expected, y’know. 
All seven carers similarly commented on their charges’ ordeals. Comments referred in the 
same way to how much worse the transplant experience had been, compared to previous 
episodes of chemotherapy. Ruby, who cared for Quentin, commented that 
I think he was a lot sicker than he thought he was going to be. 
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Bronnie (carer) complained that information about the ordeal of transplant and its after-
math was, in retrospect, too vague and non-specific: 
…because all we were told, the exact words that that one of the ladies in the hospital said was “You 
are going to feel like a washed out dishrag for about three to four months,” and I thought “Okay,” 
but that can cover a lot of things, and it didn’t really specify anything, so without anything being 
specified it is hard to know what it is… 
RELATIONSHIP BETWEEN DISSATISFACTION AND ORDEAL 
Pooling the instances of mention in all interviews – those of patients and carers – we noted 
that in the first set of interviews dissatisfaction with medical information was coded twice 
in the first interviews among the 18 interviewees (10 patients and eight carers). There were 
five instances of mention of ordeal in the first interview. 
In the second interviews, there were 31 instances of dissatisfaction offered by 13 inter-
viewees. There were 30 mentions of ordeal by the 13 interviewees. These observations 
suggest that personal experience of the ordeal of transplantation increases awareness of 
the limitations of conventional medical information. 
DISCUSSION 
The results of this small qualitative study demonstrate that the experience of ASCT can 
cause a radical reappraisal of the adequacy of the information provided before the proce-
dure. The ordeal of treatment changed approval to disappointment at the inadequacy of 
preparation. We conclude that, at least in this small cohort of patients, ASCT is not some-
thing that could be adequately communicated. It is not, indeed, possible to convey the ex-
perience of any extreme treatment, however conscientiously the clinical staff may try. No 
amount of telling can create the experience in the listener. Only the experience itself can 
take the patient through its threats, its pain, loneliness, despair and degradation 28 29. 
Informed consent in such contexts is therefore flawed. One of the basic requirements for 
adequate consent is material disclosure 21, but material disclosure of the details of the 
transplant experience does not achieve the purpose of preparing patients and carers for 
what it is actually like to go through the ordeal. 
We suggest that clinicians consider changing the nature and purpose of the consent pro-
cess. They need, of course, to respect all the present criteria of competence, voluntariness, 
material disclosure, recommendation, understanding, voluntary decision and autonomous 
authorisation 21 22, but there is also a clear need to go further. What seems to have been 
missing from the present process was a commitment to provide the support that patients 
and their carers needed during the ordeal. Informed consent, as presently construed, is on-
ly a reasonable beginning. We believe that it should be supplemented by an implicit con-
tractual undertaking to be present throughout the ordeal 27.  If clinicians are to be judged as 
sincere in their commitment to providing good care for patients undergoing major treat-
ment, we argue that they will need to provide information and assurances that would allow 
a patient to sign a document containing something along these lines: 
The procedure that I will undergo has been explained to me by the clinician primarily responsible for 
my care to a level with which I am satisfied.  
I have raised my particular concerns, and they have been adequately discussed.  
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I understand that no one can completely convey what I will experience during treatment, but the 
responsible clinician and his team have undertaken to continue to explain – to the best of their abil-
ity and knowledge –  what is happening to me, what needs to be done to help me, how long each 
episode will last in the course of my illness and treatment, and what its outcome is likely to be. 
I understand that the experience of treatment may be different to anything that I can imagine. The 
clinician and team have contracted to answer my ongoing questions and those of my designated 
family member(s) and/or carer(s) to the best of their knowledge and ability as the treatment course 
evolves, and as they deliver appropriate and competent care. 
 
CONCLUSION 
If this qualitative study can be further generalised, informed consent might become a part 
of an implicit contract between patient and clinician, in which the clinician undertakes the 
heavy responsibility of providing expert care and compassionate support throughout any 
extreme treatment. We do not believe that this commitment is too much to expect of those 
who routinely use dangerous and debilitating treatments. In the present study, it is note-
worthy that the clinical staff was praised in the interviews before the transplant, but not 
after the transplant. This is not to say that they failed to deliver excellent care. It does sug-
gest that patients and their carers perceive a need for clinicians to offer more specific sup-
port for each issue – such as severe mucositis, the need for strict isolation, severe pain, de-
bility – as it arises, offering comfort, explanation, and the reassurance that each encoun-
tered threat is familiar and temporary. They need to offer choices and make recommenda-
tions about ways to relieve symptoms and deal with crises, and they need to do these 
things personally and with their team, showing their physical presence 27, their concern for 
the welfare of patients, and their familiarity with each issue that arises during the disturb-
ing process of treatment. Informed consent to disruptive treatment should not be an end in 
itself. It is better construed as the beginning of a complex relationship that places heavy 
responsibility for continuing care on clinicians who undertake extreme treatments. It may 
not be possible to prepare people adequately by giving information before the ordeal, but it 
should be possible, by attending to the specific experiences of each patient, to forestall the 
patient Colin’s complaint that 
I could never ever comprehend what I was going through at the time.   
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